MetaCap

Pyxis Oncology Inc. (PYXS)

NASDAQ: PYXSHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.81+0.13 (+7.74%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

PYXS stock chart

Technical analysis

Key statistics

All statistics
Market cap
$216.49M
EPS (TTM)
-$1.27
52-week range
1.03 – 5.55
Day range
1.70 – 1.99
Volume / Avg
3.05M / 1.06M
Beta
—

52-week range

$1.03$5.55

PYXS stock today

On Nov 20, PYXS ended the session at $1.81, adding $0.13 (7.74%), versus the S&P 500's 3.70% decline. Volume was 2.9x the average at 3.05M shares, a sign of unusually heavy trading. At this level, PYXS sits near the bottom of its 52-week range of $1.03 to $5.55: 67.4% below the high, set on Nov 26, 2025 and 75.7% above the low.

PYXS is up 57.4% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 62.3%. Pyxis Oncology has posted a net loss over the last twelve months (EPS of -$1.27), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Pyxis Oncology

Company profile

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Thomas Civik
Headquarters
Boston, MA
Employees
56
IPO year
2021

Financial highlights

Full financials

In fiscal 2025, Pyxis Oncology generated $13.9 million in revenue, down 14.2% from fiscal 2024, the first decline in the 6 years shown. Pyxis Oncology reported a net loss of $79.6 million, compared with a loss of $77.3 million a year earlier. Gross margin was 82.8% (down from 97.1%) and operating margin -609.2%.

Pyxis Oncology annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$13.86M$16.15M———
Growth-14.17%————
Net income$-79.62M$-77.33M$-73.79M$-120.72M$-75.97M
EPS (diluted)$-1.28$-1.32$-1.85$-3.65$-8.95

Analyst forecast

Forecast

Consensus (9 analysts)

strong_buy

Avg. price target

$8.22+354.14%

  • Strong buy 1
  • Buy 7
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $5.00High $19.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.24 vs $-0.27
Surprise
+11.11%

PYXS news

All PYXS news

Pyxis Oncology peers

Health Care sector
PYXS peer companies
CompanyPrice% ChgMarket capCompare
KROSKeros Therapeutics Inc.11.08-2.72%$217.44Mvs PYXS
RCKTRocket Pharmaceuticals Inc.1.95-7.58%$217.74Mvs PYXS
ARCTArcturus Therapeutics Holdings Inc.7.45-1.97%$214.73Mvs PYXS
IMRXImmuneering Corporation Class A3.38-2.03%$218.90Mvs PYXS
ENTAEnanta Pharmaceuticals Inc.7.62-4.51%$222.19Mvs PYXS
CYPHCypherpunk Technologies Inc.1.41-18.02%$210.15Mvs PYXS
VNDAVanda Pharmaceuticals Inc.3.45-6.13%$208.32Mvs PYXS
FTHFaeth Therapeutics Inc.7.88-9.32%$203.65Mvs PYXS

Indexes, lists and sector

Pyxis Oncology stock FAQ

What is Pyxis Oncology's stock price today?

PYXS last traded at $1.81 as of Nov 20, 4:00 PM EST, up 7.74% on the day. Prices are delayed at least 15 minutes.

Who is Pyxis Oncology's CEO?

Mr. Thomas Civik is the chief executive officer of Pyxis Oncology Inc., which has about 56 employees.

What is the PYXS 52-week high?

The 52-week high for PYXS is $5.55 and the 52-week low is $1.03. The stock is currently 67.4% below its high.

Compare PYXS